Dyne Therapeutics Inc. (DYN)
Dyne Therapeutics Inc. (DYN) Stock Price, Analysis & Data
| Bid | 19.01 |
| Market Cap | 4.88B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -519.4M |
| Beta | 1.08 |
| EPS (ttm) | -3.32 |
| PE Ratio (ttm) | n/a |
| Forward PE | -7.83 |
| P/B (ttm) | 6.17 |
| P/S (ttm) | n/a |
| Earnings Date | Nov 5, 2026 |
| Ask | 32.69 |
| Volume | 1,317,571 |
| Avg. Volume (20D) | 2,243,304 |
| Open | 25.90 |
| Previous Close | 25.70 |
| Day's Range | 25.30 - 26.41 |
| 52-Week Range | 11.64 - 27.30 |
| Analyst | Strong Buy |
| Price Target | 40 (52.96%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About DYN
Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases usin...
Financial Performance
In 2025, Dyne Therapeutics's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -446.21M, an increase of 40.58%.
Financial StatementsAnalyst Forecast
According to 15 analyst ratings, the average rating for DYN stock is "Strong Buy". The 12-month stock price forecast is 40, which is upside of 52.96% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
